Update of EULAR recommendations for the treatment of systemic sclerosis

…, J Fransen, J Avouac, M Becker… - Annals of the …, 2017 - ard.bmj.com
The aim was to update the 2009 European League against Rheumatism (EULAR)
recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic …

[HTML][HTML] Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

…, W Meyer, A Janssen, M Backhaus, M Becker… - Arthritis research & …, 2009 - Springer
Introduction Anti-PM/Scl antibodies are present in sera from patients with polymyositis (PM),
systemic sclerosis (SSc), and PM/SSc overlap syndromes. The prevalence of antibodies …

Involvement of functional autoantibodies against vascular receptors in systemic sclerosis

…, L Czirják, I Lukitsch, M Becker… - Annals of the …, 2011 - ard.bmj.com
Background Systemic sclerosis (SSc) features autoimmunity, vasculopathy and tissue fibrosis.
The renin-angiotensin and endothelin systems have been implicated in vasculopathy and …

Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis

MO Becker, A Kill, M Kutsche, J Guenther… - American journal of …, 2014 - atsjournals.org
Rationale: Systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH)
portends worse outcome than other forms of PAH. Vasoconstrictive and vascular remodeling …

[PDF][PDF] Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study

M Cutolo, AL Herrick, O Distler, MO Becker… - Arthritis & …, 2016 - Wiley Online Library
Objective To identify nailfold videocapillaroscopic features and other clinical risk factors for
new digital ulcers (DUs) during a 6‐month period in patients with systemic sclerosis (SSc). …

“To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity

…, V Riccieri, O Koneva, G Cuomo, MO Becker… - Seminars in arthritis and …, 2012 - Elsevier
OBJECTIVES: To determine if mixed connective tissue disease (MCTD) can be considered
an independent clinical entity, to compare 3 different classification criteria for MCTD (…

[HTML][HTML] Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis

…, AA Kühl, J Günther, M Radic, MO Becker… - Arthritis research & …, 2014 - Springer
Introduction Vasculopathy, inflammatory fibrosis and functional autoantibodies (Abs) are
major manifestations of systemic sclerosis (SSc). Abs directed against the angiotensin II type 1 …

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

…, G Fiori, M Bokarewa, V Riccieri, M Becker… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the safety and effectiveness of tocilizumab and abatacept in systemic
sclerosis (SSc)-polyarthritis or SSc-myopathy. Methods 20 patients with SSc with refractory …

Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis

L Krause, MO Becker, CS Brueckner… - Annals of the …, 2010 - ard.bmj.com
Objective To assess and analyse nutritional status in patients with systemic sclerosis (SSc)
and identify possible associations with clinical symptoms and its prognostic value. Methods …

COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD

…, A Garaiman, S Jordan, MO Becker… - Annals of the …, 2020 - ard.bmj.com
During the current global outbreak of coronavirus disease 2019 (COVID-19), risk stratification
of patients is of utmost importance. Currently, patients> 65 years and those with preexisting …